Research that Identifies
Undiscovered Value in the MicroCap Market


Nexeon Medsystems, Inc. Email List: Click to Subscribe

View Company Website: Click to View

Market Data: Yahoo Finance, Bloomberg, SEC Filings

Report Link: Updated Research Report (Dated 05/04/2018)

Symbol: NXNN
Analyst: Howard Halpern
Taglich Rating: Speculative Buy
Price Target: $2.00
Time Horizon: 12 Months
Rating Established: January 9, 2018
Price When Established: $1.01
Most Recent Report: May 4, 2018
Price When Issued: $0.85

What's New

Nexeon Medsystems Reports 1Q18 Results

On May 21, 2018, Nexeon Medsystems reported 1Q18 results for the three-months ended March 31, 2018.

NXNN reported 1Q18 net loss of $950,000 or ($0.03) per share, on revenue of $2.9 million. In the year-ago period the company reported a net loss of $1.7 million or ($0.08) per share on revenue of $9,000.

Taglich Brothers estimated 1Q18 revenues of $1.7 million and a net loss of $1.6 million or ($0.06) per share.

Company Description

Nexeon Medsystems, Inc., headquartered in Dallas, TX, is a global medical device company focused on providing neurostimulation products to improve the quality of life for patients suffering from neurological diseases. NXNN’s Belgian-based Medi-Line subsidiary provides global medical device outsource manufacturing solutions for existing customers and long term supply contracts with Fortune 50 companies.

Company Reports

Updated Research Report (Dated May 4, 2018)

Initial Research Report (Dated January 9, 2018)


Please view our current disclosure and disclaimer on our most recent research report.